PT  - JOURNAL ARTICLE
AU  - Keywan Sohrabi
AU  - Damiano Librizzi
AU  - Abass Sohrabi
AU  - Michael Scholtes
AU  - Helmut Hoeffken
AU  - Ulrich Koehler
AU  - Volker Gross
TI  - Pressure supported nasal inhalation improving penetration of particles into the human lung
DP  - 2012 Sep 01
TA  - European Respiratory Journal
PG  - P1139
VI  - 40
IP  - Suppl 56
4099  - http://erj.ersjournals.com/content/40/Suppl_56/P1139.short
4100  - http://erj.ersjournals.com/content/40/Suppl_56/P1139.full
SO  - Eur Respir J2012 Sep 01; 40
AB  - We here report on a new method to facilitate the pressure supported nasal long-term inhalation. The method is developed and technically realized by company NLI GmbH, Germany.We examined the efficacy of the method by screening the deposition in nasal and thoracic airways. We used 99mTc-nanocoll to identify the activity scintigraphically in various respiratory sections.This study included 10 patients (f = 5, m = 5), age range 49 to 75 years, presenting several COPD stages (GOLD I-III). The NLI system generated particle sizes from 1-2 µm. The pressure support was adjusted to 10 mbar.We could show that deposition in the lung periphery by using the pressure supported transnasal application will increase significantly compared with conventional methods. The usual method produced an average nasal deposition of 5.9 MBq and a periphery deposition of 9.6 MBq, whereas NLI method results in an average nasal deposition of 4.2 MBq and a periphery deposition of 12.9 MBq, respectively.Our study showed that it was possible to penetrate even in periphery pulmonary tissue in COPD patients by using the NLI system. In additon, we achieved an enhancement of the thoracic deposition of 99mTc-nanocoll, when recorded a reduction of activity in the nasopharyngeal zone. Further clinical trials with drug applications will be necessary to confirm the clinical relevance.